Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could inhaling the TB vaccine make it work better?

NCT ID NCT06246851

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving the BCG vaccine as a mist breathed into the lungs works better than the usual injection under the skin. It includes 36 healthy adults who have already had BCG, some with type 2 diabetes and some without. Researchers will measure immune responses through blood tests and a lung wash 14 days after vaccination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy adults aged 18-65 years * Resident in or near Oxford for the duration of the study period * Provide written informed consent * Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner (or review summary care record, if available) * Allow the investigator to register volunteer details with a confidential database (The Over- volunteering Protection Service) to prevent concurrent entry into clinical studies/trials * Agreement to refrain from blood donation during the course of the study * For persons of child-bearing potential (POCBP) only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening, vaccination and bronchoscopy * Able and willing (in the investigator's opinion) to comply with all study requirements * No clinically relevant findings on physical examination * Screening IGRA negative * Willing to be tested for evidence of SARS-CoV-2 infection and to allow public health notification of the results if required * Previously vaccinated with the BCG (at least 12 months prior to enrolment, as evidenced by a visible scar or documentation in medical or occupational health records) * Group C only - Documented diagnosis of T2DM (made at least 12 months prior to enrolment) initiated on a management plan with medication including use of metformin Exclusion Criteria: * Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment or during the trial follow up period * History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the study agent, any essential study procedure, sedative drugs, or any local or general anaesthetic agents * Clinically significant history of skin disorder, allergy, atopy, cancer (except BCC of the skin or CIS of the cervix), bleeding disorder, cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder (excluding T2DM in Group C only), neurological illness, psychiatric disorder, drug or alcohol abuse * Any significant autoimmune conditions or immunodeficiency (including HIV) * Previous diagnosis or treatment for TB disease or latent TB infections * Clinical, radiological, or laboratory evidence of current active TB disease or latent TB infection * Previous receipt of any investigational TB vaccine or aerosolised BCG * More than one previous BCG vaccination * Positive HBsAg, HCV or HIV antibodies * Concurrent use of oral, inhaled or systemic steroid medication or use for more than 14 days within the last 6 months (steroids used as a cream or ointment are permissible), or the use of other immunosuppressive agents concurrently or for more than 14 days within the last 6 months * Administration of immunoglobulins and/or any blood products within the three months preceding the planned study vaccination date * Administration of a live vaccine within the preceding 28 days prior to enrolment * Administration of any other non-live vaccine within the preceding 14 days prior to enrolment * Pregnancy, lactation or intention to become pregnant during study period * Previously resident for more than 12 months concurrently in the rural areas of a tropical climate where significant non-tuberculous mycobacterial exposure is likely * Any other clinically significant abnormality of screening blood or urine tests * Any other significant disease, disorder, or finding, which, in the opinion of the investigator, may either put the volunteer at risk, affect the volunteer's ability to participate in the study or impair interpretation of the study data * A body mass index (BMI) of \<18.5 or \>45 Group A or B Specific Exclusions: * Any clinically significant respiratory disease, including asthma * Current smoker (defined as any smoking including e-cigarettes in the last 3 months) * Current use of any medication or other drug taken through the nasal or inhaled route including cocaine or other recreational drugs * Any nasal, pharyngeal, or laryngeal finding which precludes bronchoscopy * Shares a household with someone with clinically significant immunodeficiency (either from infection or medication) who is deemed to be at risk of developing disseminated BCG infection if exposed to BCG * An HBA1c at screening of \> 48mmol/Lmol * Clinically significant abnormality on screening chest radiograph * Clinically significant abnormality of lung function testing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tuberculosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre for Clinical Vaccinology and Tropical Medicine

    Oxford, Oxfordshire, OX3 7LE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.